Driven by the rising prevalence of cancers and the precision medicine revolution, the sector reached a valuation of USD 7 billion across the seven major markets in 2025. The United States remains the dominant player, accounting for approximately 60% of that total. With roughly 330,000 incident cases identified annually across these regions, pharmaceutical developers are aggressively targeting resistant mutations and complex tumor profiles to capture market share.

Industry analysts highlight a transition from first-generation therapies toward more specialized regimens. While osimertinib currently serves as the global standard of care for non-small cell lung cancer, newer entries like amivantamab and the recently approved sunvozertinib are intensifying competition. The pipeline is particularly robust, featuring late-stage candidates such as zipalertinib and firmonertinib, which aim to address specific genetic subsets like Exon 20 insertions. As these next-generation treatments move toward commercialization, they are expected to reshape treatment standards and provide new options for patients who have exhausted traditional therapeutic paths.